Computerized Neuropsychological Assessment Devices: Joint Position Paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology
Computerized Neuropsychological Assessment Devices: Joint Position Paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology
复制标题
DOI：
10.1080/13854046.2012.663001
复制
发表时间：
2012-01-01
影响因子：
3.9
通讯作者：
Naugle, Richard I.
中科院分区：
文献类型：
--
作者：
Bauer, Russell M.;Iverson, Grant L.;Naugle, Richard I.
美国临床神经心理学学会和美国国家神经心理学学会的这份联合立场文件阐述了我们对计算机化神经心理评估设备(CNAD)的适当标准和惯例的立场。在这篇文章中，我们首先定义了CNAD，并将它们与考官管理的神经心理学工具区分开来。然后，我们阐述了与在医疗保健环境中开发和使用CNAD相关的八个关键问题的立场声明。这些陈述涉及(A)CNAD开发商提出的设备营销和性能声明；(B)在适当的终端用户进行CNAD管理和解释时涉及的问题；(C)技术(硬件/软件/固件)问题；(D)隐私、数据安全、身份验证和测试环境；(E)心理测量发展问题，特别是可靠性和效度；(F)影响考生与CNAD互动的文化、经验和残疾因素；(G)使用计算机化的测试和报告服务；以及(H)需要检查CNAD环境中的回答有效性和努力程度。本文旨在为CNADs的测试开发人员和用户提供指导，以促进准确和适当地使用计算机化测试，使临床效用最大化，并将误用风险降至最低。本文中提出的立场着眼于平衡两方面的需要，一是让原本服务不足的患者能够获得经过验证的CNAD，二是确保此类测试的开发和使用得当、适当，并适当考虑患者的福利和护理质量。
This joint position paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology sets forth our position on appropriate standards and conventions for computerized neuropsychological assessment devices (CNADs). In this paper, we first define CNADs and distinguish them from examiner-administered neuropsychological instruments. We then set forth position statements on eight key issues relevant to the development and use of CNADs in the healthcare setting. These statements address (a) device marketing and performance claims made by developers of CNADs; (b) issues involved in appropriate end-users for administration and interpretation of CNADs; (c) technical (hardware/software/firmware) issues; (d) privacy, data security, identity verification, and testing environment; (e) psychometric development issues, especially reliability and validity; (f) cultural, experiential, and disability factors affecting examinee interaction with CNADs; (g) use of computerized testing and reporting services; and (h) the need for checks on response validity and effort in the CNAD environment. This paper is intended to provide guidance for test developers and users of CNADs that will promote accurate and appropriate use of computerized tests in a way that maximizes clinical utility and minimizes risks of misuse. The positions taken in this paper are put forth with an eye toward balancing the need to make validated CNADs accessible to otherwise underserved patients with the need to ensure that such tests are developed and utilized competently, appropriately, and with due concern for patient welfare and quality of care.